CSF2 and autoimmune disease: GM-CSF antagonism (e.g., via anti-GM-CSF or GM-CSFR antibodies) are also undergoing clinical trials for treating inflammatory or autoimmune diseases (e.g., rheumatoid arthritis) (23, 24).